Intra-lesional interleukin-2 for the treatment of in-transit melanoma.

  title={Intra-lesional interleukin-2 for the treatment of in-transit melanoma.},
  author={Kirsty Usher Boyd and Bret Michael Wehrli and Claire L. F. Temple},
  journal={Journal of surgical oncology},
  volume={104 7},
PURPOSE To investigate the role of intra-lesional interleukin-2 (IL-2) injection for treatment of in-transit melanoma metastases. METHODS Consecutive patients with in-transit metastases were treated with intra-lesional IL-2 injections. Two independent observers evaluated response to treatment using the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. A blinded pathologist confirmed clinical response with post-treatment biopsies. RESULTS Thirty-nine patients were included… CONTINUE READING